Press Release
2018 - 07 - 12
Shanghai | July 12, 2018 - Dedicated to developing global antibody and recombinant protein biotherapeutics, HJB today announced a joint innovation partnership with 908 Devices, a pioneer of purpose-built analytical devices for chemical and biomolecular analysis.
HJB Co-Founder and CEO Dr. Jonathan Zhao said, “HJB is going to bring multiple assets into global clinical trial. With ZipChip Platform, we will be able to further streamline internal processes and improve data quality to get results faster, ultimately accelerating clinical analysis and trials.”
HJB partners with forward-leaning thought leaders and innovative technology developers that can aide in their like-minded goal of developing meaningful therapeutics at lower cost to dramatically expand global access to vital medicines in underserved markets. HJB has recently launched a world-class pharmaceutical development facility in Hangzhou, Zhejiang where only leading-edge technologies — including the 908 Devices ZipChip platform— will be integrated into their on-site processes.
"We are truly excited about our partnership with HJB and the role 908 Devices can play in their overarching mission to develop vital, accessible medicines.," said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. "HJB is extremely innovative and has a clear vision for how ZipChip can give them the edge they need in all stages of biopharma development and production."
About 908 Devices
908 Devices is setting off a revolution in how chemical analysis gets done. 908 Devices offers point-of-need chemical and biomolecular analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. These purpose-built and user-centric devices serve the life science, field forensics and other applied markets. 908 Devices is headquartered in the heart of Boston where it researches, designs and manufactures innovative products based on high-pressure mass spectrometry™ (HPMS) and microfluidic separation technology. For more information, visit 908devices.com.
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)
Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at 2023 ESMO GI Annual Congress